产品
编 号：F747236
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1807960-57-1
产品详情
生物活性：
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody.
体内研究：
Lesofavumab (46B8; 15 mg/kg; i.v.; single dose) 能够保护小鼠免受突变型 B 型流感病毒的致命性。Animal Model:DBA/2?J mice, B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966 infection model
Dosage:15 mg/kg
Administration:Intravenous administration, single dose, 24, 48 or 72?h post infection
Result:Treatment at 24 and 48 h post infection resulted in 100% protection, with the only exception of mice infected with B/Russia/1/1969 that showed a 60% protection when treatment commenced at 48?h. Even when given at 72?h post infection, 48B8 was highly efficacious resulting in 100% protection against the B/Brisbane/60/2008, B/Victoria/504/2000 and B/Massachusetts/3/1966 strains, 75% protection against B/Wisconsin/1/2010 and 50% protection against B/Russia/1/1969.
体外研究：
Lesofavumab (MHAB5553A) 与血凝素 (HA) 残留酯酶结构域的一个保守表位结合，血凝素是 B 型流感病毒上的一种主要免疫显性表面糖蛋白，并在内体中阻断 HA 介导的膜融合。Lesofavumab (46B8) 能够中和所有 11 种与 >70 年人类感染相关的 IBV 菌株，IC50 值范围为 0.58-0.95 nM。Lesofavumab (46B8; 0-100 ng/mL) 在体外阻断膜融合并诱导抗体依赖性细胞毒性 (ADCC)。
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody.
体内研究：
Lesofavumab (46B8; 15 mg/kg; i.v.; single dose) 能够保护小鼠免受突变型 B 型流感病毒的致命性。Animal Model:DBA/2?J mice, B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966 infection model
Dosage:15 mg/kg
Administration:Intravenous administration, single dose, 24, 48 or 72?h post infection
Result:Treatment at 24 and 48 h post infection resulted in 100% protection, with the only exception of mice infected with B/Russia/1/1969 that showed a 60% protection when treatment commenced at 48?h. Even when given at 72?h post infection, 48B8 was highly efficacious resulting in 100% protection against the B/Brisbane/60/2008, B/Victoria/504/2000 and B/Massachusetts/3/1966 strains, 75% protection against B/Wisconsin/1/2010 and 50% protection against B/Russia/1/1969.
体外研究：
Lesofavumab (MHAB5553A) 与血凝素 (HA) 残留酯酶结构域的一个保守表位结合，血凝素是 B 型流感病毒上的一种主要免疫显性表面糖蛋白，并在内体中阻断 HA 介导的膜融合。Lesofavumab (46B8) 能够中和所有 11 种与 >70 年人类感染相关的 IBV 菌株，IC50 值范围为 0.58-0.95 nM。Lesofavumab (46B8; 0-100 ng/mL) 在体外阻断膜融合并诱导抗体依赖性细胞毒性 (ADCC)。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备